Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its ...

On March 31, 2025, Phathom launched a celebrity partnership with Kenan Thompson as part of the GERD IS NO JOKE campaign, marking his first public discussion about living with GERD and finding relief ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

Arvinas (NASDAQ:ARVN) is scheduled to announce Q1 earnings results on Thursday, May 1st, before market open. The consensus ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of ...

Arvinas, Inc. (NASDAQ: ARVN) recently presented data from the first-in-human clinical trial of arv-102, the company’s investigational proteolysis targeting chimera (protac) leucine-rich repeat kinase ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about determining which modality best fits a potential target than about choosing a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...